<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007058</url>
  </required_header>
  <id_info>
    <org_study_id>LAB05-0326</org_study_id>
    <nct_id>NCT01007058</nct_id>
  </id_info>
  <brief_title>Markers of Response to Intravesical Bladder Cancer Therapy</brief_title>
  <official_title>Markers of Response to Intravesical Bladder Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flight Attendant Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this laboratory research study is to see if researchers can predict whose cancer&#xD;
      will stay in remission and whose will return in patients receiving treatment for bladder&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, researchers are looking at markers that they could use to identify - at an&#xD;
      early time point - those patients who might not respond to this treatment. This would allow&#xD;
      researchers to provide future patients with information about their chances of responding to&#xD;
      such treatment. And, with this information, researchers could better counsel those patients&#xD;
      who might benefit from a different therapy at an earlier time point.&#xD;
&#xD;
      Treatment with BCG or BCG plus interferon is currently the most effective nonsurgical&#xD;
      treatment for superficial bladder cancer. However, at this time, there is no reliable test&#xD;
      that can help researchers predict which patients will respond to this therapy. You will be&#xD;
      receiving BCG or BCG plus interferon therapy as planned by your physician. This is a standard&#xD;
      therapy that will be decided by your doctor and based on your disease characteristics. If you&#xD;
      agree to take part in this study, your participation will not affect the treatment you will&#xD;
      receive in any way. Your follow-up and disease monitoring will be done according to standard&#xD;
      routines.&#xD;
&#xD;
      By participating in this study, you agree to provide researchers with 4 tablespoons (or as&#xD;
      much as you can produce) of urine at the following time points.&#xD;
&#xD;
        1. Before you start therapy.&#xD;
&#xD;
        2. Just before and 4 hours after your last treatment (which usually occurs 6 weeks after&#xD;
           start of treatment).&#xD;
&#xD;
        3. Just before and 4 hours after your last treatment of the second course of therapy (which&#xD;
           is usually about 3 months after the beginning of the first course of therapy.&#xD;
&#xD;
      In addition, you will provide researchers with a bladder wash sample. This sample will be&#xD;
      collected during routine catheterization (for your planned treatment) or during your routine&#xD;
      cystoscopic exam. Bladder wash samples will be collected at the following time points.&#xD;
&#xD;
        1. Before you start therapy.&#xD;
&#xD;
        2. Just before your last treatment (which usually occurs 6 weeks after start of treatment).&#xD;
&#xD;
        3. At your first routine cystoscopic follow-up (which usually occurs at 3 months).&#xD;
&#xD;
        4. At your second routine cystoscopic follow-up (which usually occurs at 6 months).&#xD;
&#xD;
      Your follow-up cystoscopies and maintenance therapy will be done according to routine care as&#xD;
      decided by your doctor and are not affected by your participation in this study. You will be&#xD;
      part of the study for about 24 months after beginning the treatments. At the end of that&#xD;
      period, between 23 and 27 months, you will be checked with cystoscopy and cytology to see if&#xD;
      the tumor has come back, as part of standard of care.&#xD;
&#xD;
      In addition, information will be collected from your medical chart about other medications&#xD;
      that you are taking and other conditions, such as diabetes or heart disease, that you may&#xD;
      have. Information will also be collected about previous treatment that you have had for&#xD;
      bladder cancer as well as other treatments that you may receive during this study. This may&#xD;
      include treatments that are received at an outside health facility. Neither your name nor&#xD;
      your medical record number will be kept with this information. All of the information&#xD;
      collected for this study will be kept in a locked cabinet to which only the researchers have&#xD;
      access. Upon completion of the study, the information sheets will be destroyed.&#xD;
&#xD;
      This is an investigational study.&#xD;
&#xD;
      A total of 300 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Clinical tumor recurrence or progression by 24 months after initiation of intravesical immunotherapy</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Response Markers</arm_group_label>
    <description>Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 tablespoons of urine and a bladder wash sample during catheterization (for planned&#xD;
      treatment) or during routine cystoscopic exam, both samples at 4 different time points&#xD;
      before, during and after therapy courses.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Bladder cancer patients, 18 years or older, who will be receiving treatment with BCG or BCG&#xD;
        + Interferon at UT MD Anderson Cancer Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease Characteristics:&#xD;
&#xD;
          -  Histologically confirmed primary or recurrent non-muscle-invasive transitional cell&#xD;
             carcinoma with an intact bladder&#xD;
&#xD;
          -  Stage Ta, T1, or carcinoma in situ&#xD;
&#xD;
          -  Grade 1, 2, or 3&#xD;
&#xD;
          -  Primary disease site must be the urinary bladder&#xD;
&#xD;
          -  No evidence of tumor invasion of the muscularis propria by cystoscopy and biopsy&#xD;
             within the past 6 weeks&#xD;
&#xD;
          -  Upper tract imaging within the prior 12 months&#xD;
&#xD;
        Patient Characteristics:&#xD;
&#xD;
          -  Age: 18 years and above&#xD;
&#xD;
          -  Gender: Male or female&#xD;
&#xD;
          -  Life expectancy: 24 months or greater&#xD;
&#xD;
          -  Performance status: 0 - 1&#xD;
&#xD;
        Prior Therapy:&#xD;
&#xD;
          -  Biologic therapy: allowed&#xD;
&#xD;
          -  Chemotherapy: allowed&#xD;
&#xD;
          -  Radiotherapy: no prior pelvic radiotherapy&#xD;
&#xD;
          -  Surgery: recovered from prior transurethral resection&#xD;
&#xD;
        Intravesical Immunotherapy:&#xD;
&#xD;
          -  In the opinion of the treating physician, the patient must be a candidate for&#xD;
             &quot;standard of care&quot; intravesical immunotherapy, defined as&#xD;
&#xD;
               -  Induction with 6 weekly treatments of intravesical BCG followed by maintenance&#xD;
                  with 3 weekly treatments of intravesical BCG at 3 months. Continued maintenance&#xD;
                  therapy at 6 months and then every 6 months for total of 36 months (&quot;Lamm&#xD;
                  regimen&quot;) (38) is optional and left to the discretion of the physician or&#xD;
&#xD;
               -  Induction with 6 weekly treatments of intravesical BCG plus IFN-alfa-2b followed&#xD;
                  by maintenance with 3 weekly treatments of BCG plus IFN-alfa-2b at 3 months.&#xD;
                  Continued maintenance therapy at 9 months, and 15 months (&quot;O'Donnell regimen&quot;)&#xD;
                  (39) is optional and left to the discretion of the physician.&#xD;
&#xD;
          -  Patients will be included in the study based on 'intent to treat'. If, after start of&#xD;
             induction, the treating physician decides to alter the treatment regimen, patients&#xD;
             will still be included for analysis.&#xD;
&#xD;
        Special Situations:&#xD;
&#xD;
        A special situation arises when during the course of the study, a patient develops&#xD;
        recurrent tumor, and is deemed by the treating physician to require either a reinduction&#xD;
        course of BCG therapy or therapy with BCG plus Interferon. In that case, the patient will&#xD;
        remain in the protocol and, since urine cytology/FISH and cytokine responses are dependent&#xD;
        on the treatment time-table, we will start collecting urine samples all over again, as&#xD;
        already described previously in the protocol. Also, starting from the change in the&#xD;
        treatment plan, the patient's overall time in the protocol will be prolonged up to the&#xD;
        completion of a 24-month period of time.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Ongoing Pregnancy&#xD;
&#xD;
          -  Patients who are not eligible to receive standard-of-care intravesical immunotherapy&#xD;
             such as&#xD;
&#xD;
               -  histologically confirmed pure squamous cell carcinoma or pure adenocarcinoma,&#xD;
&#xD;
               -  patients with nonurothelial bladder cancer such as sarcoma, and immunocompromised&#xD;
                  patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish M. Kamat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Bladder</keyword>
  <keyword>Non-muscle-invasive transitional cell carcinoma</keyword>
  <keyword>Intact bladder</keyword>
  <keyword>Intravesical Bladder Cancer Therapy</keyword>
  <keyword>Tumor Recurrence</keyword>
  <keyword>Surrogate markers of response</keyword>
  <keyword>BCG</keyword>
  <keyword>Bacillus Calmette Gu√©rin</keyword>
  <keyword>Interferon-alfa-2b</keyword>
  <keyword>IFN-alfa-2b</keyword>
  <keyword>Interferon</keyword>
  <keyword>Fluorescence in situ hybridization</keyword>
  <keyword>FISH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

